#BEU14: Funding in Europe and deals to change business

November 5, 2014 Erin Righetti

BEU14_banner_150x75On Day Two of BIO-Europe®, we looked at how deal makers spend their days, funding for small and midsized European biotechs and some of the innovative partnership opportunities with academics.

Here are some of our top takeaways:

  • According to Michael Burnet, the CEO of Synovo GmbH encourages all small and mid-sized biotechs who approach funding from the government to have a clear business goal, be prepared to find effective partners, and eliminate poor partners up front at the beginning of seeking funding to best move forward in the future.
  • Philippe Cupers, the Deputy Head of Strategy Unit, Health Research Directorate, DG Research and Innovation at the European Commission, shared insights into the Horizon 2020 program. They
    IMG_2390rd

    Keynote panel ” A day in the life of experienced dealmakers”

    divide their funding into three parts: Phase I: concept & feasibility assessment (50,00 million euro for 6 months), Phase II: (15-20 projects/year) Innovation/R&D Activity (100% funding – 1 to 5 mill for 36 months) and Phase III has no direct funding but it does offer support via networking, training, coaching, knowledge sharing and dissemination

  • Anton Ussi – Head of Operations, EATRIS , shares that his company gives European companies access to innovative, thought leading institutions around the European Union.
  • Josh Rose – VP, Enterprise Offering Development, Quintiles, provided reasons to think about adoptive clinical trials include finding the optimal dose of a treatment, terminating trial sites that aren’t successful,sample enrichment and more
  • James Sabry – Senior VP, Global Head of Partnering, Genentech, shares there are three was value can be accomplished in a deal: cash, true valuation/development, liquidity.
  • Shaun Grady, the Vice President of Business Development Operations at AstraZeneca sees Pharma giving up some of the control they used to wield. Pharma is becoming flexible and they don’t have to own decisions all up an down the value chain. As a result, when working with the originators/program developers will continue to the program forward even into late stage development.
  • Cincinnati Children’s Hospital Medical Center recently partnered with Alexion Pharmaceuticals to create the Alexion Rare Disease Innovation Fund.
  • Imec is a company who brings silicon technology as an innovative, disposable solution by integrating optical components.  They prefer to work with partners who already have technology.

The full session “A day in the life of experienced dealmakers: Transformational deals that shaped the industry in 2014,” recorded on Tuesday, November 4, 2014, can be seen here:

video

Previous Article
Find your next drug development partner in Paris
Find your next drug development partner in Paris

Who doesn’t love Paris? Food, culture, fashion. The Eiffel Tower. But did you know that Paris is the number...

Next Article
Shifting models in life science partnering

Ahead of BIO-Europe®, Susan Herbert, Executive VP for Global Business Development and Alliance Management a...